ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
The prevalence of interstitial lung disease and bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spontaneous Pneumomediastinum in Rheumatoid Arthritis Associated Interstitial Lung Disease and Bronchiectasis: A Three-Component Pathophysiologic Framework.European journal of case reports in internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimRheumatoid arthritis (RA) is associated with an increased risk of interstitial lung disease (ILD) and bronchiectasis. Understanding the prevalence of these diseases is essential for timely diagnosis and management. Our aim was to estimate the prevalence of ILD and bronchiectasis in RA patients. STUDY DESIGN AND
methodsA systematic literature search was performed on PubMed, Embase, and Google Scholar to identify all studies performing HRCT in consecutive RA patients. Articles were screened by three independent authors in accordance with PRISMA guidelines. Random-effects meta-regression was performed to estimate the prevalence according to RA duration and C-reactive protein.
resultsTwenty-four studies comprising 2,532 RA patients were included. The estimated prevalence of ILD at the time of RA diagnosis was 8.5% (95% CI: 4.4-12.5%), increasing by 3.0 percentage points (95% CI: 2.1-3.9%) per year after RA diagnosis (P<0.0001, R²=95%). The estimated prevalence of bronchiectasis at RA diagnosis was 8.2% (95% CI: 1.6-14.7%), increasing 1.1 percentage points (95% CI: 0.3-1.9) per year after RA diagnosis (P<0.01, R²=34%). Bronchiectasis prevalence was strongly associated with C-reactive protein and increased by 3.1 percentage points (95% CI: 0.9-5.4) per unit increase in CRP (mg/dL) (p<0.01, R2=77%) Conclusion: Bronchiectasis and ILD are common pulmonary manifestations of RA, particularly in patients with long-term disease. Possibly due to the cumulative effect of chronic inflammation. Therefore, we suggest HRCT for all patients with respiratory symptoms or RA duration exceeding 5 years. This approach may facilitate earlier detection of preclinical ILD and timely intervention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.